Quarterly ResultAug 6, 2026, 11:16 AM
Genmab H1 Revenue +25% to $2.05B; Raises 2026 Guidance
AI Summary
Genmab reported strong financial results for the first half of 2026, with revenue increasing 25% to $2,051 million, primarily due to higher royalties from DARZALEX and Kesimpta, and increased EPKINLY net product sales. The company also updated its full-year 2026 financial guidance upwards for revenue and adjusted operating profit. Additionally, Genmab announced positive Phase 3 clinical trial results for epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), demonstrating statistically significant improvement in progression-free survival.
Key Highlights
- H1 2026 revenue increased 25% to $2,051 million from $1,640 million in H1 2025.
- H1 2026 royalty revenue rose 24% to $1,708 million, driven by DARZALEX and Kesimpta.
- DARZALEX net sales by J&J increased 21% to $8,171 million in H1 2026.
- EPKINLY/TEPKINLY global net sales grew 48% to $312 million in H1 2026.
- Updated 2026 full-year revenue guidance to $4.33B-$4.53B, up from $4.07B-$4.40B.
- Updated 2026 adjusted operating profit guidance to $1.07B-$1.39B.
- Announced positive Phase 3 results for epcoritamab in relapsed/refractory DLBCL.
Price Impact
More from GMAB